Table 1 MYO9B polymorphisms in Spanish patients with ulcerative colitis, Crohn's disease and controls.
| UC (n = 677) n (%) | CD (n = 627) n (%) | Controls (n = 990) n (%) | UC vs controls | CD vs controls | UC vs CD | |
|---|---|---|---|---|---|---|
| Rs2305767 | ||||||
| AA | 263 (39) | 183 (29) | 296 (30) | 3*2 p = 0.0004 | 3*2 p = 0.51 | 3*2 p = 0.001 |
| AG | 297 (44) | 318 (51) | 518 (52) | |||
| GG | 117 (17) | 126 (20) | 176 (18) | |||
| A | 823 (61) | 684 (55) | 1110 (56) | G vs A: p = 0.007 OR = 0.82 (95% CI 0.71 to 0.95) | G vs A: p = 0.40 OR = 1.06 (95% CI 0.92 to 1.23) | G vs A: p = 0.001 OR = 0.77 (95% CI 0.66 to 0.91) |
| G | 531 (39) | 570 (45) | 870 (44) | |||
| Rs1457092 | ||||||
| CC | 258 (38) | 281 (45) | 403 (41) | 3*2 p = 0.002 | 3*2 p = 0.18 | 3*2 p = 0.005 |
| CA | 282 (42) | 257 (41) | 451 (46) | |||
| AA | 137 (20) | 89 (14) | 136 (14) | |||
| C | 798 (59) | 819 (65) | 1257 (63) | A vs C: p = 0.008 OR = 1.21 (95% CI 1.05 to 1.40) | A vs C: p = 0.29 OR = 0.92 (95% CI 0.79 to 1.07) | A vs C: p = 0.0008 OR = 1.31 (95% CI 1.12 to 1.54) |
| A | 556 (41) | 435 (35) | 723 (37) | |||
| Rs2305764 | ||||||
| GG | 227 (34) | 262 (42) | 364 (37) | 3*2 p = 0.005 | 3*2 p = 0.12 | 3*2 p = 0.0008 |
| GA | 300 (44) | 269 (43) | 469 (47) | |||
| AA | 150 (22) | 96 (15) | 157 (16) | |||
| G | 754 (56) | 793 (63) | 1197 (60) | A vs G: p = 0.006 OR = 1.22 (95% CI 1.05 to 1.40) | A vs G: p = 0.11 OR = 0.89 (95% CI 0.77 to 1.03) | A vs G: p = 0.00009 OR = 1.37 (95% CI 1.17 to 1.61) |
| A | 600 (44) | 461 (37) | 783 (40) |
Genotyping was performed by TaqMan technology under conditions recommended by the manufacturer (Applied Biosystems, Foster City, California, USA).
CD, Crohn's disease; UC, ulcerative colitis.